Market Overview

UPDATE: H.C. Wainwright & Co. Initiates Coverage on Seattle Genetics on Good Potential for Adcetris

Related SGEN
Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks
Benzinga's Top Upgrades

In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Buy rating and $65.00 price target.

In the report, H.C. Wainwright & Co. noted, “We believe that Adcetris, anti-CD30-targeted antibody drug conjugate (ADC), already approved for the treatment of refractory Hodgkin's lymphoma and anaplastic large cell lymphoma, could show further robust activity allowing it to move into new cancer indications and earlier lines of therapy. While Street expectations for SGEN are high, we also believe there could be attractive upside based on prospects for Adcetris, other ADCs, and the technology platform.”

Seattle Genetics closed on Friday at $51.78.

Latest Ratings for SGEN

Nov 2015Goldman SachsInitiates Coverage onSell
Oct 2015Piper JaffrayUpgradesUnderweightNeutral
Aug 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings

Posted-In: Andrew S. Fein H.C. Wainwright & Co.Analyst Color Initiation Analyst Ratings


Related Articles (SGEN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters